Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jan 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Acute coronary syndromes; Cardiovascular disorders; Embolism and thrombosis; Myocardial infarction; Stroke
- Focus Registrational; Therapeutic Use
- Acronyms ATLAS-2-TIMI-51; ATLAS-ACS-2-TIMI-51
- Sponsors Janssen Research & Development
- 15 Nov 2021 Results of post hoc analysis assessing predictive and protective factors of early, late, and very late stent thrombosis presented at the American Heart Association Scientific Sessions 2021
- 03 Aug 2021 Results of systematic review and meta-analysis fom COMMANDER HF, ATLAS ACS 2-TIMI 51 and COMPASS; evaluating efficacy and safety of rivaroxaban in patients with coronary artery disease, heart failure and sinus rhythm, published in the European Journal of Clinical Pharmacology
- 17 May 2021 Results of Meta-Analysis from Atlas-ACS-2 TIMI-51, COMMANDER HF, COMPASS and VOYAGER PAD; assessing whether low-dose Rivaroxaban is associated with reduction in ischemic outcomes but with increased bleeding, presented at the 70th Annual Scientific Session of the American College of Cardiology